42 unknown. 42 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 42 | Unknown 42 |
| Phase 2 | 11 | Unknown 11 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg cetirizine HCl Gummy, Zyrtec tablet 10mg - Allergy | Phase 1 | Unknown | Seattle Gummy Company | 30 | 2025-05-01 | 2024-06-13 |
| Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria UB-221 - Chronic Idiopathic Urticaria | Phase 1 | Unknown | United BioPharma | 32 | 2023-12-30 | 2022-10-03 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers UB-221 - Chronic Spontaneous Urticaria | Phase 1 | Unknown | UBP Greater China (Shanghai) Co., Ltd | 15 | 2023-12-01 | 2022-05-18 |
| A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis. GR2002 injection - Atopic Dermatitis | Phase 1 | Unknown | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 40 | 2023-12-01 | 2023-12-18 |
| A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects TQC2938 Injection, TQC2938 Placebo - Asthma | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 84 | 2023-06-13 | 2024-06-10 |
| Nasal Irrigation With Combination of 0.9% NaCl and Binahong Extract (Anredera Cordifolia) 2,5% In Allergic Rhinitis extract Binahong, Isotonic saline nasal irrigation - Allergic Rhinitis, Allergic Rhinitis Due to House Dust Mite | Phase 1 | Unknown | Gadjah Mada University | 80 | 2023-05-06 | 2024-02-28 |
| A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults FB825 or Placebo in subcutaneous route, FB825 in intravenous route - Atopic Dermatitis | Phase 1 | Unknown | Oneness Biotech Co., Ltd. | 22 | 2023-05-03 | 2024-01-26 |
| A First-in-Human Study of QY211 Gel in Adult Subjects 0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo - Atopic Dermatitis | Phase 1 | Unknown | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 56 | 2023-03-01 | 2023-05-06 |
| Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects MG-ZG122 Humanized Monoclonal Antibody Injection, Placebo - Asthma | Phase 1 | Unknown | Shanghai Mabgeek Biotech.Co.Ltd | 34 | 2023-02-09 | 2024-02-23 |
| Mechanism of EGR2 in Allergic Rhinitis EGR2 - Rhinitis, Allergic | Phase 1 | Unknown | Zu-xia Ma | 3 | 2023-01-30 | 2023-02-13 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis 2mg QY201 tablets or 2mg QY201 placebo,BID, 5mg QY201 tablets or 5mg QY201 placebo,BID, 10mg QY201 tablets or 10mg QY201 placebo,QD - Atopic Dermatitis | Phase 1 / Phase 2 | Unknown | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 260 | 2022-10-01 | 2022-09-02 |
| A Study of MG-K10 in Subjects With Asthma MG-K10, Placebo - Asthma | Phase 1 / Phase 2 | Unknown | Shanghai Mabgeek Biotech.Co.Ltd | 180 | 2022-07-05 | 2023-08-21 |
| Clinical Study of Allergic Rhinitis Therapy by Stem Cells Low dose UCMSCs, Moderate dose UCMSCs, High dose UCMSCs - Allergic Rhinitis | Phase 1 | Unknown | Yantai Yuhuangding Hospital | 18 | 2022-06-13 | 2023-03-28 |
| A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects TQH2722 injection, Placebo to match TQH2722 - Atopic Dermatitis | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 48 | 2022-06-01 | 2022-06-08 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 36 | 2022-05-11 | 2022-05-31 |
| SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects RBN-3143 - Atopic Dermatitis | Phase 1 | Unknown | Ribon Therapeutics, Inc. | 72 | 2022-03-07 | 2023-10-23 |
| Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells Olfactory mucosa-derived mesenchymal stem cells, Standard treatment of type Allergic Rhinitis according to the clinical protocols, Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols - Allergic Rhinitis, Rhinosinusitis Chronic | Phase 1 / Phase 2 | Unknown | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 60 | 2022-03-01 | 2022-01-19 |
| Targeted Elimination Diet in EoE Patients Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy personalized exclusion diet based on CLE, empiric exclusion diet - Eosinophilic Esophagitis | Phase 1 / Phase 2 | Unknown | Universitaire Ziekenhuizen KU Leuven | 25 | 2022-02-16 | 2024-06-27 |
| Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients House Dust Mite Extract, Dermatophagoides Farinae - Mite Allergy, Rhinitis, Allergic | Phase 1 | Unknown | RAPHAS | 54 | 2022-01-20 | 2024-04-10 |
Showing 20 of 42. Sign in to see all of them.
Asthma (15) · Dermatitis, Atopic (11) · Rhinitis, Allergic (8) · Chronic Urticaria (2) · Conjunctivitis, Allergic (2) · Anaphylaxis (1) · Arthritis, Rheumatoid (1) · Cardiovascular Diseases (1) · Cough-Variant Asthma (1) · Dust Mite Allergy (1) · Eosinophilic Esophagitis (1) · Idiopathic Pulmonary Fibrosis (1) · Inflammation (1) · Nasal Polyps (1)
Immune System Diseases (42) · Hypersensitivity, Immediate (38) · Respiratory Hypersensitivity (23) · Respiratory Tract Diseases (23) · Bronchial Diseases (16) · Lung Diseases (16) · Lung Diseases, Obstructive (16) · Skin Diseases (14) · Skin and Connective Tissue Diseases (14) · Dermatitis (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Skin Diseases, Eczematous (11) · Skin Diseases, Genetic (11)
Fluticasone (4) · Saline Solution (3) · Budesonide (2) · Salmeterol Xinafoate (2) · Antigens, Dermatophagoides (1) · Cetirizine (1) · Dexamethasone (1) · Formoterol Fumarate (1) · Injections, Subcutaneous (1) · Mometasone Furoate (1) · Ointments (1) · Population Groups (1) · grass pollen extract, alum-adsorbed (1) · hydrocortisone acetate (1) · methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate (1)
Respirent Pharmaceuticals Co Ltd. (4) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (2) · E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (2) · Shanghai Mabgeek Biotech.Co.Ltd (2) · Amber Patterson (1) · Dermavant Sciences GmbH (1) · Evolutec Group (1) · Gadjah Mada University (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · Guy Steuer (1) · Hadassah Medical Organization (1) · Hamad Medical Corporation (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · JOSALYN CHO (1)
China (11) · United States (7) · Greece (4) · Australia (2) · South Korea (2) · Austria (1) · Belgium (1) · Indonesia (1) · Israel (1) · New Zealand (1) · Qatar (1) · Spain (1) · Taiwan (1) · Tunisia (1)
Chrysoula Doxani, MD, MSc, PhD (3) · Amber M Patterson, MD (1) · Bambang Rianto, MD OHNS (1) · Cheng Zhou, PHD (1) · Devi K Jhaveri, D.O. (1) · Friedrich Horak, MD (1) · Guy Steuer, M.D. (1) · Haig Tcheurekdjian, M.D. (1) · Horng-Chin Yan, M.D., Ph.D. (1) · Hui Zhao (1) · Ioannis Stefanidis, Professor (1) · James Lee, MD, PhD (1) · Jianzhong Zhang, PHD (1) · Josalyn L Cho, MD (1)
PMID 15764724, PMID 16164444, PMID 26706294, PMID 30471304, PMID 33496659, PMID 35870902, PMID 40221092, PMID 40760578, PMID 41144273, PMID 41469153, PMID 42212541
2009 (1)